UMaine med device spinoff Neuright receives $225K tech transfer award

Neuright Inc., a University of Maine biotech spinoff focused on the early diagnosis and treatment of peripheral neuropathy, was awarded $225,000 under the National Science Foundation’s Small Business Technology Transfer program to develop its technology for delivery to market.

Peripheral neuropathy, a condition in which nerve fibers die back from the skin, is estimated to affect more than 20 million people in the U.S. and can cause symptoms including pain, numbness and loss of limb control, according to a news release.

Diabetes is the leading cause of peripheral neuropathy. Up to 70% of the 34 million Americans with diabetes will also have peripheral neuropathy. Wide-ranging, variable symptoms make peripheral neuropathy difficult to diagnose, and while there is no cure, early intervention and treatment can help patients minimize the often-debilitating effects. Read more

Related Posts

Portland startup Marin Skincare launches lobster-based lip treatment

Portland startup Marin Skincare, known for its “lobster lotion,” is expanding that product line to include lip treatments.  Founded out of the University...

20 November 2023

UMaine scientists use eDNA to enhance river herring recovery research in Penobscot River

University of Maine researchers are seeking to gain more insight into river herring recovery in the Penobscot River using a novel...

16 November 2023

FocusMaine co-founder named group’s next president

Nearly a decade after Andrea Cianchette Maker joined forces with Michael Dubyak to launch FocusMaine, Maker will lead the organization as...

15 November 2023